These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17998762)

  • 21. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women.
    Uemura H; Yasui T; Miyatani Y; Yamada M; Hiyoshi M; Arisawa K; Irahara M
    J Endocrinol Invest; 2008 Feb; 31(2):163-8. PubMed ID: 18362509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Wołkowska-Pokrywa K; Szapska B
    Postepy Hig Med Dosw (Online); 2013 May; 67():433-41. PubMed ID: 23752595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
    Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
    J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.
    Ozer FF; Dagdelen S; Erbas T
    Horm Metab Res; 2018 Jul; 50(7):562-567. PubMed ID: 29895074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
    Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
    Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D; Neacşu E; Marinescu M; Popa O
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
    Siomou E; Challa A; Printza N; Giapros V; Petropoulou F; Mitsioni A; Papachristou F; Stefanidis CJ
    Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea.
    Foo JP; Polyzos SA; Anastasilakis AD; Chou S; Mantzoros CS
    J Clin Endocrinol Metab; 2014 Nov; 99(11):E2252-8. PubMed ID: 25148234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
    Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels.
    Martini G; Gennari L; De Paola V; Pilli T; Salvadori S; Merlotti D; Valleggi F; Campagna S; Franci B; Avanzati A; Nuti R; Pacini F
    Thyroid; 2008 Apr; 18(4):455-60. PubMed ID: 18399769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism.
    Pepene CE; Crişan N; Coman I
    Clin Invest Med; 2011 Aug; 34(4):E232. PubMed ID: 21810381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.